Cyclosporin for refractory ulcerative colitis

C. G. Loftus, E. V. Loftus, W. J. Sandborn

Research output: Contribution to journalShort surveypeer-review

37 Scopus citations

Abstract

Intravenous cyclosporin (with or without continued intravenous corticosteroids) is effective in 50-80% of patients with severe ulcerative colitis. An initial dose of 2 mg/kg/day intravenous cyclosporin appears to be as effective as 4 mg/kg/day and is thus preferred from the standpoint of safety. Long term response rates following short term treatment with intravenous cyclosporin in controlled trials ranged from 45% (without azathioprine maintenance) to 78% (with azathioprine). There is a small risk of opportunistic infection and death (1-2%) during combined cyclosporin, corticosteroid, and azathioprine therapy, but lower doses of cyclosporin may improve the safety profile. Toxicity may be reduced at a dose of 2 mg/kg/day intravenous cyclosporin.

Original languageEnglish (US)
Pages (from-to)172-173
Number of pages2
JournalGut
Volume52
Issue number2
DOIs
StatePublished - Feb 1 2003

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Cyclosporin for refractory ulcerative colitis'. Together they form a unique fingerprint.

Cite this